TREA

Preclinical development of novel small molecule malaria drugs that overcome drug

Follow

Information

  • Research Project
  • 9032430
  • ApplicationId
    9032430
  • Core Project Number
    R42AI094959
  • Full Project Number
    5R42AI094959-05
  • Serial Number
    094959
  • FOA Number
    PA-10-124
  • Sub Project Id
  • Project Start Date
    9/1/2011 - 13 years ago
  • Project End Date
    3/31/2017 - 7 years ago
  • Program Officer Name
    MCGUGAN, GLEN C.
  • Budget Start Date
    4/1/2016 - 8 years ago
  • Budget End Date
    3/31/2017 - 7 years ago
  • Fiscal Year
    2016
  • Support Year
    05
  • Suffix
  • Award Notice Date
    3/28/2016 - 8 years ago
Organizations
Information

Preclinical development of novel small molecule malaria drugs that overcome drug

DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and chloroquine-sensitive malaria. This project carries on preclinical development of a drug candidate that has been selected from this innovative class of potent antimalarials designed to overcome drug resistance. The candidate will be advanced through the ultimate stages of preclinical testing. Thus, pharmacokinetics, pharmacodynamics, pharmacology, and toxicity evaluations will be performed in both rats and monkeys. The overall goal will be completion of preclinical studies leading to approval of an Investigative New Drug (IND) application for the drug to be used in a Phase 1 human clinical trial.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R42
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    994275
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:994275\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    DESIGNMEDIX, INC.
  • Organization Department
  • Organization DUNS
    623389009
  • Organization City
    PORTLAND
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    972014830
  • Organization District
    UNITED STATES